Taysha Gene Therapies Added to the Nasdaq Biotechnology Index
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) has been officially included in the Nasdaq Biotechnology Index effective December 20, 2021. This inclusion aims to enhance the company's visibility and attract investors as it continues to advance its AAV-based gene therapy pipeline focused on treating monogenic diseases of the CNS. The Nasdaq Biotechnology Index tracks biotechnology and pharmaceutical securities that meet specific eligibility criteria, reflecting Taysha's commitment to developing curative treatments for patients.
- Inclusion in the Nasdaq Biotechnology Index is expected to increase visibility and investor awareness.
- The company has a broad pipeline focused on AAV-based gene therapies for CNS diseases.
- None.
“We are pleased to announce Taysha’s inclusion in the Nasdaq Biotechnology Index,” said RA Session II, President, Founder and CEO of Taysha. “As we continue to advance our broad pipeline and execute on our near-term clinical and regulatory milestones, inclusion in this index will enhance our visibility and expand awareness of our story with investors.”
The Nasdaq Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The Nasdaq Biotechnology Index is calculated under a modified capitalization-weighted methodology. Companies in the Nasdaq Biotechnology Index must meet eligibility requirements, including minimum market capitalization, average daily trading volume and seasoning as a public company, among other criteria. Nasdaq selects constituents once annually in December.
For more information about the Nasdaq Biotechnology Index, please visit https://indexes.nasdaqomx.com/Index/Overview/NBI.
About
View source version on businesswire.com: https://www.businesswire.com/news/home/20211215005350/en/
Company Contact:
SVP, Corporate Communications and Investor Relations
klee@tayshagtx.com
Media Contact:
carolyn.hawley@canalecomm.com
Source:
FAQ
When was Taysha Gene Therapies added to the Nasdaq Biotechnology Index?
What is the significance of the Nasdaq Biotechnology Index for Taysha (TSHA)?
What type of therapies does Taysha Gene Therapies focus on?